Viatris Greater China — Finite-lived intangible assets, net decreased by 8.9% to $4.36B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 8.9%, from $4.79B to $4.36B. This decline may warrant attention — for this metric, higher values are generally preferred.
A steady or increasing balance suggests ongoing investment in intellectual property, while a rapid decline may indicate asset aging or aggressive amortization.
The net book value of non-physical assets with a limited economic life, such as patents, licenses, or customer relations...
Standard balance sheet item for pharmaceutical companies reflecting the value of acquired product portfolios.
vtrs_segment_greater_china_finite_lived_intangible_assets_net| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $6.12B | $5.64B | $5.22B | $4.79B | $4.36B |
| QoQ Change | — | -7.7% | -7.6% | -8.2% | -8.9% |
| YoY Change | — | -7.7% | -7.6% | -8.2% | -8.9% |